Sectors
VOR
Vor Biopharma Inc.
22.48
2 x 16.33
2 x 28.87
bid
ask
-
0.17
0.75%
2 @ 05:34 PM
22.14 -0.34 (1.51%)
| Ytd | 71.87% | |
| 1y | -42.94% |
22.30
day range
22.76
6.50
52 week range
49.95
| Open | 22.50 | Prev Close | 22.65 | Low | 22.30 | High | 22.76 | Mkt Cap | 1.33B |
| Vol | 847.20K | Avg Vol | 1.15M | EPS | 180.58 | P/E | 0.12 | Forward P/E | -5.90 |
| Beta | 1.72 | Short Ratio | 8.91 | Inst. Own | 85.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 20.28 | 200-d Avg | 15.29 | 1yr Est | 39.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-12 | 2026-09 | -0.81 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.86 | -1.16 | -0.3 | -35.40% |
| 2026-05-13 | 2026-03 | -0.75 | -0.73 | 0.02 | 2.67% |
| 2026-03-30 | 2025-12 | -1.14 | 44.5 | 45.64 | 4003.51% |
| 2025-11-13 | 2025-09 | -3.06 | -121.63 | -118.57 | -3874.84% |
| 2025-08-12 | 2025-06 | -11.4 | -251.2 | -239.8 | -2103.51% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-12 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-05-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-04-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-31 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-03-30 | Jefferies | Upgrade | Buy |
Profile
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-02-02 | ANG ROBERT M.D. | Chief Executive Officer | 921.74K | Stock Award(Grant) |
| 2025-02-12 | ATTAR EYAL C | Officer | 126.63K | Sale |
| 2025-02-02 | CHAKRABORTY TIRTHA | Officer | 221.27K | Stock Award(Grant) |
| 2025-02-02 | CHOI HAN WOOK | Chief Financial Officer | 52.50K | Stock Award(Grant) |
| 2025-07-08 | MAHATME SANDESH | Chief Financial Officer | 13.88M | Stock Award(Grant) |
| 2026-08-23 | RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | TCG Crossover Management, LLC | 5.67M | 127.53M | 9.59% |
| 2026-06-29 | FMR, LLC | 4.93M | 110.87M | 8.34% |
| 2026-06-29 | FCPM III Services B.V. | 4.12M | 92.56M | 6.96% |
| 2026-06-29 | Blackrock Inc. | 3.47M | 77.96M | 5.86% |
| 2026-06-29 | Venrock Adviser, LLC | 3.04M | 68.38M | 5.14% |
| 2026-06-29 | State Street Corporation | 2.62M | 58.82M | 4.42% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.75M | 39.34M | 2.96% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.37M | 30.90M | 2.32% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.07M | 23.94M | 1.80% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 951.91K | 21.40M | 1.61% |
| 2026-05-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 542.28K | 12.19M | 0.92% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 343.95K | 7.73M | 0.58% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2025-09-19 |